HIFU market to hit $2.76 billion by 2030 as prostate cancer demand rises

The global high intensity focused ultrasound market is projected to grow from $1.66 billion in 2025 to $1.84 billion in 2026, driven by rising prostate cancer cases and broader adoption of non-invasive treatment options. The Business Research Company's latest report says North America led the market in 2025, while Asia-Pacific is expected to grow fastest through 2030.

Why it matters: - High intensity focused ultrasound is gaining traction as a non-surgical treatment for tumors, uterine fibroids and some cancers, including prostate and liver cancer. - The market’s growth reflects rising demand for less invasive care and stronger healthcare infrastructure in more regions. - The report projects the market will reach $2.76 billion by 2030, up from $1.66 billion in 2025.

What happened: - The Business Research Company released a report on the global high intensity focused ultrasound market. - The report estimates the market will rise to $1.84 billion in 2026, representing a 10.8% compound annual growth rate. - The market is projected to grow at a 10.7% CAGR from 2026 to 2030. - The report identifies North America as the largest regional market in 2025. - The report says Asia-Pacific is expected to post the fastest growth during the forecast period.

The details: - HIFU uses concentrated ultrasound waves to create localized heat and destroy targeted tissue while limiting damage to surrounding healthy tissue. - The technology is used as an alternative to traditional surgery in certain cases. - The report links past growth to rising uterine fibroid and prostate cancer cases, better ultrasound devices, higher awareness of non-invasive treatments and more trained healthcare professionals. - Future growth is expected to come from robotic HIFU systems, artificial intelligence, imaging integration, higher adoption in emerging economies, healthcare investment and portable or home-use devices. - Key trends include focused ultrasound for cancer treatment, broader non-invasive therapy use, multimodal imaging integration and minimally invasive pain relief solutions. - Prostate cancer diagnoses in England rose from 50,751 in 2022 to 55,033 in 2023, according to Prostate Cancer UK. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report also includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspot infographics, key technology analysis and updated graphics. - The report includes a free sample and the full market report.

Between the lines: - Rising prostate cancer incidence is a direct demand driver because HIFU can target cancer cells without harming nearby tissue. - The fastest-growing regions are also the ones investing more in medical infrastructure and advanced technology, which suggests HIFU adoption is tied to access as much as clinical need. - The inclusion of portable and home-use devices points to a broader push to move HIFU beyond specialized hospital settings if the technology and regulation allow it.

What's next: - The market is expected to keep expanding through 2030 as robotic systems, AI-enabled imaging and portable devices move forward. - Emerging economies are likely to become a bigger source of demand as healthcare investment rises. - The Business Research Company is promoting the report through its expert contact channels and social media presence.